Zymeworks (ZYME) to Release Quarterly Earnings on Wednesday

Zymeworks (NYSE:ZYME) is projected to announce its earnings results after the market closes on Wednesday, March 5th. Analysts expect the company to announce earnings of $0.01 per share and revenue of $45.20 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Zymeworks Stock Performance

Shares of NYSE:ZYME opened at $12.74 on Tuesday. The business’s fifty day moving average price is $14.31 and its two-hundred day moving average price is $13.59. The stock has a market cap of $877.51 million, a PE ratio of -8.49 and a beta of 1.10. Zymeworks has a one year low of $7.97 and a one year high of $17.70.

Insider Buying and Selling

In other Zymeworks news, EVP Jeffrey T. L. Smith sold 11,110 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $14.92, for a total value of $165,761.20. Following the transaction, the executive vice president now directly owns 8,890 shares of the company’s stock, valued at $132,638.80. This trade represents a 55.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ecor1 Capital, Llc acquired 204,098 shares of the business’s stock in a transaction on Friday, January 10th. The stock was bought at an average cost of $13.13 per share, for a total transaction of $2,679,806.74. Following the completion of the transaction, the director now directly owns 15,411,078 shares of the company’s stock, valued at $202,347,454.14. This trade represents a 1.34 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 603,539 shares of company stock valued at $8,384,708 and have sold 89,601 shares valued at $1,336,847. Corporate insiders own 1.92% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. HC Wainwright restated a “neutral” rating and set a $12.00 price objective on shares of Zymeworks in a report on Friday, November 22nd. Citigroup raised their price objective on Zymeworks from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, November 4th. Wells Fargo & Company raised their price objective on Zymeworks from $12.00 to $14.00 and gave the stock an “equal weight” rating in a report on Thursday, December 19th. JPMorgan Chase & Co. upgraded Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective on the stock in a report on Monday, December 16th. Finally, Leerink Partnrs upgraded Zymeworks from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $19.17.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.